N.J. Admin. Code § 10:161B-11.1

Current through Register Vol. 56, No. 9, May 6, 2024

Section 10:161B-11.1 - Authority

(a) A program applying for licensure to operate an opioid treatment program pursuant to these standards shall:

1. Provide written documentation that the applicant for licensure of the opioid treatment program has notified the governing authority of the municipality of the full scope of services, including opioid treatment, to be provided at the facility. Notification shall be subject to verification by DOH prior to issuance of a license to operate an opioid treatment program pursuant to the outpatient substance use disorder treatment license;

2. Be certified as an opioid treatment program by the Substance Abuse and Mental Health Services Administration (SAMHSA) and accredited by an accreditation body approved by SAMHSA in accordance with 42 CFR Part 8, available at http://www.samhsa.gov/laws-regulations-guidelines/substance-use-regulations-mandates#opioid. Revocation of certification by SAMHSA shall constitute the immediate withdrawal of licensure approval to operate an opioid treatment program by DCN&L ;

3. Comply with all regulations enforced by the Drug Enforcement Administration (DEA) under 21 CFR Chapter II and be registered by the DEA, at 1-800-882-9539, or online at http://www.deadiversion.usdoj.gov/index.html; and State of New Jersey Department of Law and Public Safety, Drug Control Unit, (973) 504-6351, http://www.njconsumeraffairs.gov/dcu/Pages/default.aspx, as a Narcotic Treatment Program in accordance with N.J.A.C. 8:67, before administering or dispensing opioid agonist treatment medications;

4. Provide services which meet the Federal standards set by accrediting agencies contained in 42 CFR Part 8.12, as well as the more specific State requirements of this chapter;

5. Use only those opioid agonist treatment medications approved by the Food and Drug Administration for use in opioid treatment programs for the treatment of opioid dependence;

6. Comply with the publication "Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs," issued by the Center for Substance Abuse Treatment (CSAT) as part of the Treatment Improvement Protocol Series, TIP 43 (2005), incorporated herein by reference as amended and supplemented; copies are available from the National Clearinghouse for Alcohol and Drug Information, P.O. Box 2345, Rockville, MD 20847-6686, 1-800-729-6686, http://www.cocommunity.net/agency/national-clearinghouse-alcohol-and-drug-information.html or for online download at http://store.samhsa.gov/product/TIP-43-Medication-Assisted-Treatment-for-Opioid-Addiction-in-Opioid-Treatment-Prog

7. Meet all applicable local building, zoning and other codes for the siting of an opioid treatment program;

8. Each opioid treatment program shall participate in a registry or other data management system implemented by DMHAS, submitting information in the format prescribed by DMHAS, for the purpose of preventing the enrollment of clients in more than one program and facilitating client relocation; and

9. Opioid treatment programs providing detoxification shall, in addition, comply with the following:

i. Clients receiving short-term detoxification (that is, less than 30 days) shall receive services in accordance with N.J.A.C. 10:161B-12; and

ii. Clients receiving long-term detoxification (that is, 30 days to 180 days) shall receive all services for Phase I clients required by 10:161B-11.8 and 12.

N.J. Admin. Code § 10:161B-11.1

Amended by 48 N.J.R. 2791(a), effective 12/19/2016

Amended by 55 N.J.R. 2346(a), effective 11/20/2023